Table 5.

Comparing maintenance immunosuppression between PTDM and non-PTDM groups

Maintenance ImmunosuppressionAt Discharge3 months6 months12 monthsWithin 12 months
No Post-transplant Diabetes MellitusPost-transplant Diabetes MellitusNo Post-transplant Diabetes MellitusPost-transplant Diabetes MellitusNo Post-transplant Diabetes MellitusPost-transplant Diabetes MellitusNo Post-transplant Diabetes MellitusPost-transplant Diabetes MellitusNo Post-transplant Diabetes MellitusPost-transplant Diabetes Mellitus
Tacrolimus423 (95%)181 (97%)411 (92%)179 (96%)382 (90%)176 (96%)374 (89%)171 (94%)420 (94%)181 (97%)
 Dose, mg/day10 (6, 12)
n=422
8 (6, 12)
n=179
8 (6, 12)
n=408
8 (5, 12)
n=178
7 (4.75, 12)
n=376a
6 (3.5, 10.5)
n=176a
6 (4, 10)
n=368
5 (3, 9)
n=171
7.5 (5, 11)
n=416a
6 (4.3, 10.7)
n=181a
 Trough6.3 (4.1, 8.8)
n=408
6.45 (3.6, 9)
n=178
8.4 (6.9, 10.1)
n=406
8.7 (6.9, 11)
n=178
7.4 (5.9, 9.1)
n=377
7.1 (6.1, 8.9)
n=175
6.5 (5.3, 7.8)
n=369
6.5 (5.3, 7.8)
n=171
7.6 (6.5, 8.9)
n=418
7.7 (6.6, 8.8)
n=181
Mycophenolate429 (96%)183 (98%)410 (92%)173 (93%)345 (81%)155 (84%)327 (78%)147 (81%)421 (94%)178 (96%)
 Dose1440 (1000, 2000)
n=429
1440 (1000, 2000)
n=183
1080 (1000, 1500)
n=410
1290 (1000, 1500)
n=172
1000 (1000, 1440)
n=346
1080 (1000, 1440)
n=155
1000 (1000, 1440)
n=327
1000 (720, 1440)
n=147
1080 (960, 1440)
n=421
1080 (960, 1440)
n=178
Sirolimus3 (1%)010 (2%)2 (1%)6 (1%)1 (1%)9 (2%)3 (2%)16 (4%)4 (2%)
 Dose, mg/day3.0 (0, 9)3.25 (2, 6)
n=10
3 (3, 3)
n=2
5.5 (2.5, 7)
n=6
8 (8, 8)
n=1
3 (1,4)
n=9
4 (3, 4)
n=3
3.25 (2, 5)
n=14
4 (3, 4.67)
n=3
 Trough, ng/ml4.0 (0, 9)….5.2 (3.7, 8.1)
n=9
7 (3.5, 10.5)
n=2
7.85 (5.6, 9.82)
n=6
6 (6, 6)
n=1
8.2 (5.1, 11.5)
n=9
8.35 (7.6, 9.1)
n=2
7.8 (3.8, 10.38)
n=16
7.6 (6.2, 10.5)
n=3
Everolimus001 (0%)01 (0%)1 (1%)2 (0%)1 (1%)2 (0%)1 (1%)
 Dose3….504 (3,4)63 (3,4)4
 Belatacept2 (0%)03 (1%)04 (1%)04 (1%)04 (1%)0
Prednisone368 (84%)165 (91%)364 (82%)163 (88%)341 (80%)159 (86%)338 (81%)156 (86%)375 (84%)166 (89%)
 Dose ≤5Median (IQR)
20 (20, 30)
n=356
Median (IQR)
20 (20, 55)
n=164
243 (68%)120 (75%)283 (83%)138 (87%)300 (89%)141 (90%)236 (63%)112 (67%)
 Dose >5117 (33%)41 (25%)58 (17%)21 (13%)38 (11%)15 (10%)137 (37%)54 (33%)
Cyclosporine8 (2%)3 (2%)10 (2%)3 (2%)16 (4%)4 (2%)18 (4%)5 (3%)20 (4%)5 (3%)
 Dose, mg/day312.5 (150, 575)
n=8
550 (350, 650)
n=3
250 (200, 400)
n=10
400 (300, 400)
n=3
250 (200, 300)
n=16
350 (275, 375)
n=3
200 (150, 250)
n=18
250 (200, 275)
n=5
229.17 (168.75, 304.17)
n=20
283.33 (200, 333.33)
n=5
 Trough, ng/ml65.5 (29, 314)
n=8
148 (66.5, 186.6)
n=3
279 (204, 349)
n=9
192 (167.4, 227)
n=3
162.65 (129, 237.3)
n=14
148.5 (131.9, 165.45)
n=4
171.9 (96, 214)
n=15
148 (117, 173)
n=5
182.67 (147.45, 228.67)
n=17
168.33 (158.67, 173)
n=5
  • Results are similar between those that developed post-transplant diabetes mellitus and those that did not, unless indicated. IQR, interquartile range.

  • a P≤0.05.